Rocuronium Syringes Recalled for Lack of Sterility Validation
Central Admixture Pharmacy Services is recalling rocuronium syringes due to lack of validation data for sanitization cycles, which cannot assure sterility. The recall affects 10,065 syringes distributed nationwide.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II recall without reported illnesses or injuries. The hazard—inability to assure sterility due to lack of sanitization cycle validation—represents a significant risk for an injectable medication, meeting the criterion for high severity where injury has not yet been reported but the hazard is serious.
Plain-English summary
Central Admixture Pharmacy Services Inc. is recalling rocuronium 50 mg/5 mL syringes because the company lacks validation data for its sanitization cycles, which means sterility of the product cannot be assured. The FDA classified this as a Class II recall.
The affected product consists of 10,065 syringes distributed nationwide. Multiple lot numbers are affected with expiration dates ranging from July 2023 through September 2023. Rocuronium is a prescription injectable medication.
Healthcare providers in possession of affected lots should verify their lot numbers and expiration dates against the recall list to identify if they received product subject to this recall. Those who believe they have received affected product should contact Central Admixture Pharmacy Services Inc. for further instructions regarding return or destruction of the product.
The recalled product
- Product
- rocuronium, 50 mg /5 mL, (10 mg/mL), 5 mL Syringe, Rx only, Central Admixture Pharmacy Services, Inc., 7935 Dunbrook Road, Suite C, San Diego, CA 92126, NDC: 71286-6010-1
- Manufacturer
- Central Admixture Pharmacy Services Inc
- Hazard
- sterility-failure
- validation-failure
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (20)
- Lot: 17-270519
- Exp. 7/16/2023
- 17-270605
- Exp. 7/17/2023
- 17-270684
- Exp. 7/18/2023
- 17-270898
- Exp. 7/20/2023
- 17-271074
- Exp. 7/24/2023
- 17-271324
- Exp. 7/27/2023
- 17-271603
- Exp. 8/1/2023
- 17-271670
- Exp. 8/2/2023
- 17-272529
- Exp. 8/17/2023
- 17-272883
- Exp. 8/23/2023
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27